SHIEF Stock Chart & Stats
$0.08
>-$0.01(-3.91%)
At close: 4:00 PM EDT
$0.08
>-$0.01(-3.91%)
Day’s Range― - ―
52-Week Range$0.05 - $0.18
Previous CloseN/A
Volume1.91M
Average Volume (3M)6.00
Market Cap
$81.95M
Enterprise Value$78.73M
Total Cash (Recent Filing)$8.39M
Total Debt (Recent Filing)$25.03M
Price to Earnings (P/E)―
Beta0.53
Next Earnings
Apr 29, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding1,074,157,600
10 Day Avg. Volume20
30 Day Avg. Volume6
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)-5.76
Price to Sales (P/S)1.71
P/FCF Ratio-9.83
Enterprise Value/Market Cap0.96
Enterprise Value/Revenue1.35
Enterprise Value/Gross Profit2.66
Enterprise Value/Ebitda-24.42
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)$97.22M
Bulls Say, Bears Say
Bulls Say
Strong Revenue GrowthRevenue growth of 58.2% demonstrates strong commercial progress for the company’s lead product and expands the base from which future profitability can develop. Continued top-line expansion over the next several quarters could improve operating leverage and support greater investment in commercialization.
Improving Gross MarginThe improvement in gross margin indicates that stronger sales are accompanied by better underlying economics, rather than growth occurring solely at low profitability. If maintained, this trend can help the company retain more revenue to fund operations and narrow its remaining earnings deficit.
Debt EliminatedEliminating reported debt materially reduces scheduled financing obligations and interest-related pressure, giving management more flexibility as the business scales. Although the balance sheet remains fragile, a zero-debt position removes one important source of financial risk over the medium term.
Bears Say
Continued Net LossesDespite rapid revenue growth and improved margins, the company remains substantially loss-making, showing that current commercial scale is not yet sufficient to cover the full cost base. Persistent losses could delay self-sustaining profitability and require further operational improvement before earnings become durable.
Negative Shareholders’ EquityNegative equity indicates a fragile capital structure and limits financial flexibility even after debt was reduced to zero. The worsening deficit can increase dependence on external funding and raises the potential for dilution or other financing actions if losses continue.
Ongoing Cash BurnThe company has not yet converted improving income-statement performance into positive cash generation, with both operating and free cash flow remaining negative. Continued cash burn can elevate funding needs and constrain the ability to finance commercialization from internally generated resources.
Shield Therapeutics News
SHIEF FAQ
What was Shield Therapeutics PLC’s price range in the past 12 months?
Shield Therapeutics PLC lowest stock price was $0.05 and its highest was $0.18 in the past 12 months.
What is Shield Therapeutics PLC’s market cap?
Shield Therapeutics PLC’s market cap is $81.95M.
When is Shield Therapeutics PLC’s upcoming earnings report date?
Shield Therapeutics PLC’s upcoming earnings report date is Apr 29, 2027 which is in 188 days.
How were Shield Therapeutics PLC’s earnings last quarter?
Shield Therapeutics PLC released its earnings results on Aug 20, 2026. The company reported $0 earnings per share for the quarter.
Is Shield Therapeutics PLC overvalued?
According to Wall Street analysts Shield Therapeutics PLC’s price is currently Overvalued.
Does Shield Therapeutics PLC pay dividends?
Shield Therapeutics PLC does not currently pay dividends.
What is Shield Therapeutics PLC’s EPS estimate?
Shield Therapeutics PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Shield Therapeutics PLC have?
Shield Therapeutics PLC has 1,074,157,600 shares outstanding.
What happened to Shield Therapeutics PLC’s price movement after its last earnings report?
Shield Therapeutics PLC reported an EPS of $0 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Shield Therapeutics PLC?
Currently, no hedge funds are holding shares in SHIEF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Shield Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-24.32%
12-Months-Change
Fundamentals
Return on Equity
64.57%
Trailing 12-Months
Asset Growth
-10.81%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Shield Therapeutics PLC
Shield Therapeutics plc, a commercial stage specialty pharmaceutical company, focuses on development and commercialization of clinical-stage pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Feraccru, a non-salt based oral therapy for adults to treat the iron deficiency with or without anemia. Shield Therapeutics plc was incorporated in 2008 and is based in Gateshead, the United Kingdom.